DAMONA PHARMACEUTICALS Trademark

Trademark Overview

On Tuesday, September 21, 2021, a trademark application was filed for DAMONA PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the DAMONA PHARMACEUTICALS trademark a serial number of 97037937. The federal status of this trademark filing is NOTICE OF ALLOWANCE - CANCELLED as of Monday, June 24, 2024. This trademark is owned by Damona Pharmaceuticals Inc. C/O Centre for Addiction and Mental Health. The DAMONA PHARMACEUTICALS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of pharmaceutical preparations and medicines for the prevention and treatment of neuropsychiatric and neurological disorders and neurodegenerative diseases
damona pharmaceuticals

General Information

Serial Number97037937
Word MarkDAMONA PHARMACEUTICALS
Filing DateTuesday, September 21, 2021
Status690 - NOTICE OF ALLOWANCE - CANCELLED
Status DateMonday, June 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 12, 2024

Trademark Statements

NOT AVAILABLE"PHARMACEUTICALS"
Goods and ServicesResearch and development of pharmaceutical preparations and medicines for the prevention and treatment of neuropsychiatric and neurological disorders and neurodegenerative diseases

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSunday, October 24, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDamona Pharmaceuticals Inc. C/O Centre for Addiction and Mental Health
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressToronto, ONTARIO M6J1H4
CA
Party NameDamona Pharmaceuticals Inc. C/O Centre for Addiction and Mental Health
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressToronto, ONTARIO M6J1H4
CA

Trademark Events

Event DateEvent Description
Tuesday, June 28, 2022NON-FINAL ACTION WRITTEN
Friday, September 24, 2021NEW APPLICATION ENTERED
Sunday, October 24, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 23, 2022ASSIGNED TO EXAMINER
Monday, September 26, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, June 28, 2022NON-FINAL ACTION E-MAILED
Tuesday, June 28, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, September 26, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 26, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, December 1, 2023TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Sunday, October 23, 2022SUSPENSION LETTER WRITTEN
Sunday, October 23, 2022LETTER OF SUSPENSION E-MAILED
Sunday, October 23, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, April 26, 2023SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sunday, June 25, 2023SUSPENSION LETTER WRITTEN
Sunday, June 25, 2023LETTER OF SUSPENSION E-MAILED
Sunday, June 25, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, January 19, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Saturday, January 27, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 2, 2024ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Wednesday, February 7, 2024ELECTRONIC RECORD REVIEW COMPLETE
Wednesday, February 21, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 21, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 12, 2024PUBLISHED FOR OPPOSITION
Tuesday, March 12, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 7, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, June 24, 2024NOTICE OF ALLOWANCE CANCELLED
Monday, June 24, 2024CASE RETURNED TO EXAMINATION

Related Keywords

pharmaceuticals damona neurological neuropsychiatric disorders neurodegenerative diseases treatment prevention development pharmaceutical preparations